Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to Receipt of Approval for Drug Clinical Trail by a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

27 January 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

Stock code: 600196	Stock abbreviation: Fosun Pharma	Announcement No.: Lin2021-012
Bond code: 136236	Bond abbreviation: 16 Fosun 01
Bond code: 143020	Bond abbreviation: 17 Fosun 01
Bond code: 143422	Bond abbreviation: 18 Fosun 01
Bond code: 155067	Bond abbreviation: 18 Fosun 02
Bond code: 155068	Bond abbreviation: 18 Fosun 03

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to Receipt of Approval for Drug Clinical Trial by a Subsidiary

The board of directors of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產

業 發 展 有限 公 司 ) ("Fosun Pharmaceutical Industrial"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company"), has received the approval regarding FN-1501injection (the "Investigational New Drug") for phase I dosage exploration clinical trials for patients with advanced malignant solid tumors and phase II clinical trials for patients with advanced hepatocellular carcinoma from the National Medical Products Administration.("NMPA").

Fosun Pharmaceutical Industrial intends to start the approved clinical trials of the Investigational New Drug for the indication in the PRC (excluding Hong Kong and Macau Special Administrative Region and Taiwan region, hereinafter the same) recently when preparations are done.

II. Research on the Investigational New Drug

The Investigational New Drug, a new type of small molecule chemical drug transferred from

1

China Pharmaceutical University and developed by the Group (i.e. the Company and its subsidiaries/units), is proposed to be mainly used for the treatment of leukemia and solid tumor.

As at the date of this announcement, the Investigational New Drug is at phase I clinical trials in the United States and Australia (for the treatment of leukemia, solid tumor), the PRC (for the treatment of leukemia). The Investigational New Drug for the treatment of acute myeloid leukemia has been granted Orphan Drug Designation by the U.S. FDA (U.S. Food and Drug Administration).

As at the date of this announcement, small molecule targeted drugs marketed in the PRC for the treatment of advanced hepatocellular carcinoma mainly include Regofinil tablets (拜万戈® ), Sorafenib tosylate tablets (多吉美® ) from Bayer HealthCare Company Ltd., and Lenvatinib mesylate tablets （乐卫玛® ）from Eisai China Inc.. According to the latest IQVIA CHPA data (provided by IQVIA, a world-leading provider of professional medical and health information and strategic consultation; IQVIA CHPA data represents the drug sales market in hospitals with more than 100 wards in the PRC and the actual sales of drugs may differ from the IQVIA CHPA data due to differences in their respective distribution channels), the sales of drugs with the same indication of the Investigational New Drug in the PRC in 2019 amounted to approximately RMB1,302.82 million.

As at December 2020, the Group has cumulatively invested in the R&D of the Investigational New Drug in an aggregate amount of approximately RMB98.95 million (unaudited; including license fee) at this stage.

III. Risk Warning

As required by the relevant laws and regulations in the PRC, the Investigational New Drug for the approved indication is subject to a series of clinical studies and the approval from the national drug evaluation authority in the PRC before it can be marketed. There are certain risks in the R&D of new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and marketing of new drugs is a long-term task involving various uncertainties. Investors should be aware of the investment risks.

Announcement is hereby given.

2

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

27 January 2021

3